Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing

This review focuses on the emerging monoclonal antibody market for infectious diseases and the metric ton scale manufacturing requirements to meet global demand. Increasing access to existing antibody-based products coupled with the unmet need in infectious disease will likely exceed the current exi...

Descripción completa

Detalles Bibliográficos
Autores principales: Whaley, Kevin J, Zeitlin, Larry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Passive SF – Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103258/
https://www.ncbi.nlm.nih.gov/pubmed/34259613
http://dx.doi.org/10.1080/21645515.2021.1930847
_version_ 1784707518938742784
author Whaley, Kevin J
Zeitlin, Larry
author_facet Whaley, Kevin J
Zeitlin, Larry
author_sort Whaley, Kevin J
collection PubMed
description This review focuses on the emerging monoclonal antibody market for infectious diseases and the metric ton scale manufacturing requirements to meet global demand. Increasing access to existing antibody-based products coupled with the unmet need in infectious disease will likely exceed the current existing global manufacturing capacity. Further, the large numbers of individuals infected during epidemics such as the ongoing COVID-19 pandemic emphasizes the need to plan for metric ton manufacturing of monoclonal antibodies by expanding infrastructure and exploring alternative production systems.
format Online
Article
Text
id pubmed-9103258
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91032582022-05-14 Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing Whaley, Kevin J Zeitlin, Larry Hum Vaccin Immunother Passive SF – Review This review focuses on the emerging monoclonal antibody market for infectious diseases and the metric ton scale manufacturing requirements to meet global demand. Increasing access to existing antibody-based products coupled with the unmet need in infectious disease will likely exceed the current existing global manufacturing capacity. Further, the large numbers of individuals infected during epidemics such as the ongoing COVID-19 pandemic emphasizes the need to plan for metric ton manufacturing of monoclonal antibodies by expanding infrastructure and exploring alternative production systems. Taylor & Francis 2021-07-14 /pmc/articles/PMC9103258/ /pubmed/34259613 http://dx.doi.org/10.1080/21645515.2021.1930847 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Passive SF – Review
Whaley, Kevin J
Zeitlin, Larry
Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
title Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
title_full Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
title_fullStr Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
title_full_unstemmed Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
title_short Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
title_sort emerging antibody-based products for infectious diseases: planning for metric ton manufacturing
topic Passive SF – Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103258/
https://www.ncbi.nlm.nih.gov/pubmed/34259613
http://dx.doi.org/10.1080/21645515.2021.1930847
work_keys_str_mv AT whaleykevinj emergingantibodybasedproductsforinfectiousdiseasesplanningformetrictonmanufacturing
AT zeitlinlarry emergingantibodybasedproductsforinfectiousdiseasesplanningformetrictonmanufacturing

Ejemplares similares